116 results about "Glutarimide" patented technology

The present disclosure relates to compounds of Formula (I) and Formula (II) or salts, enantiomers, stereoisomers, solvates, isotope enriched analogs, prodrugs or polymorphs thereof, and uses thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds of formula (I) or salts, enantiomers, stereoisomers, solvates, isotope enriched analogs, prodrugs or polymorphs thereof as active ingredients and uses thereof. # imgabs0 #

The present disclosure relates to a compound of formula (I) or a salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof and a use of the compound. The present disclosure further relates to a pharmaceutical composition containing, as an active ingredient, the compound of formula (I) or the salt, enantiomer, stereoisomer, solvate, isotopically enriched analog, prodrug or polymorph thereof and a use of the composition. A series of compounds designed and synthesized in the present disclosure can effectively prevent or treat celeblon protein-related diseases or disorders, comprising tumors or cancers.

The invention discloses heat-resistant polymethyl methacrylate, a preparation method thereof and an optical film. The heat-resistant polymethyl methacrylate comprises a methyl methacrylate repetitive unit, a glutarimide repetitive unit and an N-methyl methacrylamide repetitive unit, and the sum of the number of the glutarimide constitutional unit and the number of the N-methyl methacrylamide constitutional unit is 1-20 mol% of the total number of the constitutional units. The glutarimide structural unit can be obtained by further cyclization reaction of an N-methyl methacrylamide structural unit, and the cyclization rate can be increased to 80-90% by adding a cyclization accelerator such as triethylamine, so that the thermal stability of the resin is improved, and the water absorption rate is reduced. The material can be used for preparing an optical film, has excellent heat resistance and moisture resistance, and is suitable for the field of optical display.

Disclosed in the present invention are a glutarimide compound, and the use thereof. Specifically disclosed are a compound as represented by formula (VII-0) and a pharmaceutically acceptable salt thereof.

Provided are compounds of formula (I) and formula (II) or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogues, prodrugs, or polymorphs thereof, and uses thereof. Further provided are a pharmaceutical composition containing the compound of formula (I) as an active ingredient, or the salt, enantiomer, stereoisomer, solvate, isotopically enriched analogue, prodrug, or polymorph thereof, and a use thereof.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

A CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG), a composition thereof and the use thereof, and a protein degradation agent of a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG) and the use thereof. Specifically, the CRBN small molecule ligand compound is as represented by (I). R1 and R2 are selected from one or more of a bicyclic ring attached to the pyridazine mother nucleus, H, alkyl, OR, F, CN, CF3, NR2, Ph and 4-Py; Y is selected from one or more of CH, CD, CF and N; R3 is selected from one or more of OR, NR2, CHR2 and C≡CR; R4 is selected from H or more; R4 is selected from H or alkyl.

The application discloses a bacteriostatic and deodorizing zeolite cat litter and a preparation method thereof, and belongs to the technical field of zeolite cat litter preparation. The bacteriostatic and deodorizing zeolite cat litter is composed of the following components in parts by weight: 55-75 parts of modified zeolite, 3-6 parts of bacteriostatic gel, 2-5 parts of adhesive, and 1-3 parts of filler. The modified zeolite is prepared from sulfamic acid, N,N-dimethylformamide, lignocellulose and zeolite, and the bacteriostatic agent is prepared from four-arm polyethylene glycol, succinic anhydride, triethylamine, N-hydroxyl glutarimide, 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride and polylysine. The zeolite cat litter prepared by the method has excellent water absorption, antibacterial property and deodorizing property.

The invention belongs to the technical field of medicine synthesis processes, and particularly relates to a preparation method of high-yield and high-purity buspirone hydrochloride. According to the method, 8-(2-pyrimidinyl)-8-aza-5-5-azonium spiro [4.5] decane hydrobromide (pyrimidino piperazine quaternary ammonium salt for short) and 3, 3-tetramethylene glutarimide are taken as raw materials, a mixed solvent of methylbenzene and n-amyl alcohol and / or n-hexanol is taken as a solvent, buspirone can be generated in the presence of sodium carbonate without adding a phase transfer catalyst, and buspirone can be obtained through acid adjustment and extraction. After toluene reverse phase impurity removal, a water phase is adjusted to be alkaline, an ethanol solution of hydrogen chloride is added after toluene extraction, and buspirone hydrochloride solid is directly separated out. The preparation process has a very good cleaning effect on impurities, and the obtained buspirone hydrochloride is high in purity, high in process yield, good in atom economy and low in output of three wastes.

The invention discloses immobilized hydantoin enzyme. The immobilized hydantoin enzyme comprises an immobilized carrier, a cross-linking agent and recombinant hydantoin enzyme, wherein the recombinant hydantoin enzyme is connected with the immobilized carrier through the cross-linking agent by a chemical bond. In addition, the immobilized hydantoin enzyme is cross-linked again through a bifunctional cross-linking agent, and the 3-isobutyl glutarimide can be converted into the (R)-(-)-3-(carbamyl methyl)-5-methylhexanoic acid by the re-cross-linked immobilized enzyme with higher stability.

The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.

This invention belongs to the field of pharmaceutical chemistry technology, and discloses a compound and its uses. Specifically, it relates to a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG), its composition, and its application. It also relates to a protein degrading agent based on a CRBN small molecule ligand compound based on a pyridazine-glutarimide core skeleton (PDG) and its application. Specifically, the CRBN small molecule ligand compound is shown in (Ⅰ): wherein R... 1 and R 2 Selected from one or more of the following: fused rings attached to a pyridazine core, H, alkyl, OR, F, CN, CF3, NR2, Ph, 4-Py; Y selected from one or more of CH, CD, CF, and N; R 3 Selected from one or more of OR, NR2, CHR2, and C≡CR; R 4 Selected from H or alkyl.

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

Provided are: a resin composition containing 30-85 parts by mass of an acrylic resin (A) and 15-70 parts by mass of an aromatic vinyl resin (B), the acrylic resin (A) contains 60-95% by mass of a (meth) acrylic monomer unit and 5-40% by mass in total of at least one selected from the group consisting of a glutaric anhydride unit, a glutaric imide unit, an N-substituted maleimide unit and a lactone ring unit. The aromatic vinyl resin (B) contains 55-93% by mass of an aromatic vinyl monomer unit and 7-45% by mass of an N-substituted maleimide unit.

The present invention provides degron bodies with carbon-linked E3 ubiquitin ligase targeting moieties (degrons) that can be linked to targeting ligands for proteins selected for degradation in vivo, methods and compositions for their use, and methods for their preparation.

The present invention provides a method for manufacturing acrylic resins, acrylic resin films, and acrylic resin molded articles that exhibit excellent resistance to roll contamination and heat resistance during film formation. [Solution] The method for producing an acrylic resin molded article includes a step of melt-molding an acrylic resin using an extruder, the resin containing methyl methacrylate units and having one or more ring structures selected from the group consisting of glutarimide rings, lactone rings, maleic anhydride rings, glutaric acid anhydride rings, and maleimide rings in its main chain. If the content of methyl methacrylate dimers in the acrylic resin and the content of methyl methacrylate dimers in the acrylic resin molded article are A [ppm by weight] and B [ppm by weight], respectively, then the formula [(AB) / A] × 100 The reduction rate of methyl methacrylate dimers calculated by this method is 50% or more.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The present disclosure provides a compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and / or treat diseases or disorders associated with the cereblon protein.

This invention provides Degron compounds which bind to cereblon which is a component of the E3 ubiquitin ligase. The Degrons provided herein can be used to modulate the activity of cereblon either alone or as covalently linked to a Tail. Alternatively, the Degron can be linked to a Targeting Ligand which binds to a Target Protein for protein degradation.

The present disclosure relates to the technical field of molecular glue decomposers, and in particular to a compound of formula I based on a sulfur / oxygen substituted glutarimidylimide isoindolinone skeleton and its applications. The present disclosure further relates to a compound of formula A and its applications. JPEG2026502207000117.jpg44146

The present disclosure relates to the technical field of molecular glue degraders, and particularly to a sulfur / oxygen substituted glutarimide-isoindolinone skeleton-based compound of Formula I, and uses thereof. The present disclosure further pertains to a compound of Formula A and its uses.

The invention discloses a synthesis method of a glutarimide compound, which comprises the following steps: by taking a compound pentanediol compound as an initial raw material, firstly activating hydroxyl by a halogenating reagent or a sulfonyl chloride compound, then reacting with sodium cyanide to prepare a glutaronitrile compound, and finally hydrolyzing under the action of Bronsted acid to obtain the glutarimide compound. And carrying out cyclization to generate the glutarimide compound. The synthetic method has the advantages of short steps, low cost and simplicity and convenience in operation, is suitable for large-scale industrial production, and can be used as a drug intermediate or used for researching potential drugs.

The present invention discloses crystals of naphthofuran-substituted glutarimide compounds, a method for producing the same, and uses thereof, and more specifically, the present invention discloses crystals of compound (1) and the production thereof. JPEG2025531599000016.jpg3499

The present disclosure provides a compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and / or treat diseases or disorders associated with the cereblon protein.

Provided is an engineered polypeptide capable of catalyzing the asymmetric hydrolysis of 3-isobutylglutarimide to generate (R)-(−)-3-(carbamoylmethyl)-5-methylhexanoic acid. The engineered polypeptide has high stereoselectivity, high catalytic activity, good process stability and thermal stability, and tolerance to high product concentrations, and has good prospects for industrial applications.

The present disclosure provides a compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof, and uses thereof. The present disclosure also provides pharmaceutical compositions comprising, as an active ingredient, the compound of Formula (I) or salts, enantiomers, stereoisomers, solvates, or polymorphs thereof, and uses thereof. The series of compounds designed and synthesized in the present disclosure can effectively prevent and / or treat diseases or disorders associated with the cereblon protein.

A resin composition containing 30 to 85 parts by mass of an acrylic resin (A) and 15 to 70 parts by mass of an aromatic vinyl resin (B), wherein the acrylic resin A contains 60 to 95% by mass of (meth)acrylic monomer units and 5 to 40% by mass in total of at least one selected from the group consisting of glutaric anhydride units, glutarimide units, N-substituted maleimide units, and lactone ring units, and the aromatic vinyl resin (B) contains 55 to 93% by mass of aromatic vinyl monomer units and 7 to 45% by mass of N-substituted maleimide units. A plate-shaped molded article and a multilayered article are provided.

The invention relates to the field of organic synthesis, in particular to a preparation method and application of glutarimide compounds, and the preparation method comprises the following steps: in the presence of formic acid, a compound II reacts with formamide to prepare a compound I. According to the preparation method, glutaric acid compounds and formamide are adopted as starting raw materials, and the yield of 80% or above can be obtained under the condition that no additional reaction solvent is used only by adding a catalytic amount of formic acid into a reaction system. # imgabs0 #

The present disclosure relates to a compound of Formula (I) or a salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor. The present disclosure also relates to a compound of Formula (I′) or a pharmaceutically acceptable salt, a solvate, an isotopically enriched analog, a tautomer, a polymorph, a stereoisomer thereof, or a mixture of stereoisomers thereof, and their use for treating a tumor.

Disclosed are a glutarimide isoindolinone skeleton-based compound represented by formula (I) or a salt, enantiomer, stereoisomer, solvate, isotope-enriched analogue, prodrug or polymorphic substance thereof, and a use thereof in the treatment and prevention of cereblon protein-related diseases or disorders including tumors or cancers.